Choate Investment Advisors decreased its holdings in Celgene Corporation (NASDAQ:CELG) by 0.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,591 shares of the biopharmaceutical company’s stock after selling 238 shares during the quarter. Choate Investment Advisors’ holdings in Celgene Corporation were worth $3,843,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Marble Harbor Investment Counsel LLC raised its position in shares of Celgene Corporation by 3.9% in the 1st quarter. Marble Harbor Investment Counsel LLC now owns 6,735 shares of the biopharmaceutical company’s stock valued at $838,000 after buying an additional 250 shares in the last quarter. Pioneer Investment Management Inc. raised its position in shares of Celgene Corporation by 15.7% in the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after buying an additional 710,584 shares in the last quarter. Jaffetilchin Investment Partners LLC raised its position in shares of Celgene Corporation by 5.5% in the 1st quarter. Jaffetilchin Investment Partners LLC now owns 3,045 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 160 shares in the last quarter. CIBC World Markets Inc. raised its position in shares of Celgene Corporation by 27.5% in the 1st quarter. CIBC World Markets Inc. now owns 105,626 shares of the biopharmaceutical company’s stock valued at $13,143,000 after buying an additional 22,764 shares in the last quarter. Finally, Holderness Investments Co. acquired a new position in shares of Celgene Corporation in the 1st quarter valued at approximately $205,000. Institutional investors and hedge funds own 79.48% of the company’s stock.

Celgene Corporation (NASDAQ CELG) opened at $104.50 on Wednesday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The firm has a market cap of $81,211.74, a price-to-earnings ratio of 16.12, a price-to-earnings-growth ratio of 0.80 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. equities analysts forecast that Celgene Corporation will post 6.67 EPS for the current year.

WARNING: “Choate Investment Advisors Has $3.84 Million Holdings in Celgene Corporation (CELG)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/22/choate-investment-advisors-has-3-84-million-holdings-in-celgene-corporation-celg.html.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the transaction, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,227 shares of company stock worth $2,843,956. Corporate insiders own 0.95% of the company’s stock.

CELG has been the subject of several analyst reports. Morgan Stanley cut shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research report on Thursday, October 5th. BTIG Research restated a “hold” rating on shares of Celgene Corporation in a research report on Sunday, October 22nd. Cantor Fitzgerald restated a “hold” rating and issued a $112.00 target price on shares of Celgene Corporation in a research report on Monday, October 30th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 target price for the company in a research report on Monday, October 23rd. Finally, Citigroup Inc. cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. Celgene Corporation currently has an average rating of “Buy” and a consensus price target of $139.57.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.